logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10221138 B1

PDFFull Text
Date of Patent:
Mar. 05, 2019

Filed:

Jun. 26, 2014

Biaryl derivatives as gpr120 agonists

Applicant:

Lg Chem, Ltd., Seoul, KR;

Inventors:

Young Kwan Kim, Daejeon, KR;

Sang Yun Park, Daejeon, KR;

Hyun Woo Joo, Daejeon, KR;

Eun Sil Choi, Daejeon, KR;

Assignee:

LG CHEM, LTD., Seoul, KR;

Attorney:

Rothwell, Figg, Ernst & Manbeck, P.C.

Primary Examiner:

Joseph R Kosack

Int. Cl.
CPC ...
C07C 59/68 (2006.01); C07C 59/72 (2006.01); C07C 217/80 (2006.01); C07C 323/52 (2006.01); C07C 323/53 (2006.01); C07D 213/30 (2006.01); C07D 213/64 (2006.01); C07D 213/65 (2006.01); C07D 213/70 (2006.01); C07D 213/74 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 213/643 (2006.01);
U.S. Cl.
CPC ...
C07D 213/643 (2013.01); C07C 59/68 (2013.01); C07C 59/72 (2013.01); C07C 217/80 (2013.01); C07C 323/52 (2013.01); C07C 323/53 (2013.01); C07D 213/30 (2013.01); C07D 213/64 (2013.01); C07D 213/65 (2013.01); C07D 213/70 (2013.01); C07D 213/74 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05);
Abstract

The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

Find Patent Forward Citations

Loading…